60 related articles for article (PubMed ID: 20090101)
1. Antibody detection against HPV16 E7 & GP96 fragments as biomarkers in cervical cancer patients.
Bolhassani A; Zahedifard F; Taslimi Y; Taghikhani M; Nahavandian B; Rafati S
Indian J Med Res; 2009 Nov; 130(5):533-41. PubMed ID: 20090101
[TBL] [Abstract][Full Text] [Related]
2. The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL /6 mouse model.
Mohit E; Bolhassani A; Zahedifard F; Taslimi Y; Rafati S
Scand J Immunol; 2012 Jan; 75(1):27-37. PubMed ID: 21916914
[TBL] [Abstract][Full Text] [Related]
3. Immuno-Stimulating Peptide Derived from HMGB1 is More Effective Than the N-Terminal Domain of Gp96 as an Endogenous Adjuvant for Improvement of Protein Vaccines.
Talebi S; Bolhassani A; Azad TM; Arashkia A; Modaresi MH
Protein Pept Lett; 2017; 24(3):190-196. PubMed ID: 28000571
[TBL] [Abstract][Full Text] [Related]
4. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies.
Bolhassani A; Zahedifard F; Taghikhani M; Rafati S
Vaccine; 2008 Jun; 26(26):3362-70. PubMed ID: 18471945
[TBL] [Abstract][Full Text] [Related]
5. [Expression, purification, and serum antibody detection of HPV16 E6 in cervical cancer patients].
Gao YE; Guo JZ; Zhang J; Song TB; Yan XJ
Ai Zheng; 2006 Nov; 25(11):1374-9. PubMed ID: 17094904
[TBL] [Abstract][Full Text] [Related]
6. Significance of serum antibodies against HPV E7, Hsp27, Hsp20 and Hp91 in Iranian HPV-exposed women.
Ramezani A; Aghakhani A; Soleymani S; Bavand A; Bolhassani A
BMC Infect Dis; 2019 Feb; 19(1):142. PubMed ID: 30755156
[TBL] [Abstract][Full Text] [Related]
7. [Expression purification and clinical application of high-risk HPV16 E4 gene].
Gao YE; Hui H; Zhang J; Fan JB; Yan XJ
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Aug; 33(8):676-81. PubMed ID: 18772505
[TBL] [Abstract][Full Text] [Related]
8. Serological study in Tunisian cervical cancer patients.
Achour M; Kochbati L; Zeghal D; Kahla S; Maalej M; Zouari F; Oueslati R
Pathol Biol (Paris); 2009 Jul; 57(5):415-9. PubMed ID: 18586408
[TBL] [Abstract][Full Text] [Related]
9. Nanobody against the E7 oncoprotein of human papillomavirus 16.
Li S; Zhang W; Jiang K; Shan H; Shi M; Chen B; Hua Z
Mol Immunol; 2019 May; 109():12-19. PubMed ID: 30849663
[TBL] [Abstract][Full Text] [Related]
10. High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma.
Ressler S; Scheiden R; Dreier K; Laich A; Müller-Holzner E; Pircher H; Morandell D; Stein I; Viertler HP; Santer FR; Widschwendter A; Even J; Jansen-Dürr P; Capesius C; Zwerschke W
Clin Cancer Res; 2007 Dec; 13(23):7067-72. PubMed ID: 18056184
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections.
Mohit E; Bolhassani A; Zahedifard F; Seyed N; Eslamifar A; Taghikhani M; Samimi-Rad K; Rafati S
Mol Immunol; 2013 Jan; 53(1-2):149-60. PubMed ID: 22926003
[TBL] [Abstract][Full Text] [Related]
12. HPV-16-related proteins as the serologic markers in cervical neoplasia.
Park JS; Park DC; Kim CJ; Ahn HK; Um SJ; Park SN; Kim SJ; Namkoong SE
Gynecol Oncol; 1998 Apr; 69(1):47-55. PubMed ID: 9570998
[TBL] [Abstract][Full Text] [Related]
13. HPV 16 E7 antibody levels in cervical cancer patients: before and after treatment.
Di Lonardo A; Marcante ML; Poggiali F; Venuti A
J Med Virol; 1998 Mar; 54(3):192-5. PubMed ID: 9515768
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients.
Silins I; Avall-Lundqvist E; Tadesse A; Jansen KU; Stendahl U; Lenner P; Zumbach K; Pawlita M; Dillner J; Frankendal B
Gynecol Oncol; 2002 May; 85(2):333-8. PubMed ID: 11972397
[TBL] [Abstract][Full Text] [Related]
15. The association of human papillomavirus type 16 E6 and E7 antibodies with stage of cervical cancer.
Fisher SG; Benitez-Bribiesca L; Nindl I; Stockfleth E; Muller M; Wolf H; Perez-Garcia F; Guzman-Gaona J; Gutierrez-Delgado F; Irvin W; Gissmann L
Gynecol Oncol; 1996 Apr; 61(1):73-8. PubMed ID: 8626121
[TBL] [Abstract][Full Text] [Related]
16. Analysis of antibody response to HPV 16 and HPV 18 antigens in Tunisian patients.
Achour M; Kahla S; Zeghal D; Kochbati L; Mongi M; Zouari F; Oueslati R
Viral Immunol; 2009 Feb; 22(1):7-16. PubMed ID: 19210223
[TBL] [Abstract][Full Text] [Related]
17. Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients.
Ravaggi A; Romani C; Pasinetti B; Tassi RA; Bignotti E; Bandiera E; Odicino FE; Ragnoli M; Donzelli C; Falchetti M; Calza S; Santin AD; Pecorelli S
Arch Virol; 2006 Oct; 151(10):1899-916. PubMed ID: 16732494
[TBL] [Abstract][Full Text] [Related]
18. Cell-mediated immune response to human papillomavirus 16 E7 peptide pools in patients with cervical neoplasia.
Lee YS; Lee CW; Song MJ; Ho EM; Kim CJ; Park TC; Kim TG; Park JS
Acta Obstet Gynecol Scand; 2011 Dec; 90(12):1350-6. PubMed ID: 21916856
[TBL] [Abstract][Full Text] [Related]
19. [Gene characterization of E6 and E7 gene of human papillomavirus of 15 cervical cancer in Beijing].
Ren Z; Wu HW; Song J
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Apr; 23(2):88-90. PubMed ID: 20104743
[TBL] [Abstract][Full Text] [Related]
20. Identification of antibodies against human papillomavirus type 16 E4 and E7 proteins in sera of patients with cervical neoplasias.
Stoian M; Repanovici R
Rev Roum Virol; 1994; 45(3-4):185-92. PubMed ID: 7619739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
